Liver Transplant Clinical Trials
Here are the 6 most popular medical studies for liver transplant
recombinant P-selectin glycoprotein ligand Ig fusion protein for Ischemia Reperfusion Injury
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal vein and to the recipient intravenously prior to reperfusion. This study is an extension of the recent pilot study YSPSL-0002 with an almost identical study protocol. The rationale of this and the previous study is based on the recent observation that P-selectin expression has been associated in liver grafts with prolonged cold storage times and rejection. By examining biomarkers of IRI including P-selectin by immunohistochemistry and/or quantitative PCR, liver histology and hepatic blood flow using established techniques, the goal of this study is to evaluate the feasibility of using these modalities for future studies of safety and efficacy.
Health Advocate for Liver Transplant Complications
This trial assesses an intervention to support pediatric liver transplant patients by facilitating medical care, finances and access to resources, with the goal to improve communication and self-management for better outcomes.
LIFT and REAP for Liver Cirrhosis
This trial will test a new intervention to improve frailty in patients awaiting liver transplant. The intervention includes an evaluation by a physical therapist, an individualized home exercise prescription, and exercise tracking using a smart phone application. The investigators also aim to perform "Realistic Effort Action Planning" in a subset of patients to determine if this enhances the intervention.
Liver Transplant for Bile Duct Cancer
This trial is for patients with intrahepatic cholangiocarcinoma who have achieved 6 months of disease stability while receiving standard chemotherapy. If eligible, they will be listed for transplantation. After transplantation, they will be followed for disease recurrence and overall survival.
Non-alcoholic Fatty Liver Disease Clinical Trials
View 10 Non-alcoholic Fatty Liver Disease medical studies.
TEST Intervention for Liver Transplant
This trial will study how available technology combined with transplant center resources and caregiver support can optimize medication adherence, quality of life, and health outcomes among new liver transplant recipients at 3 centers.
Peritoneal Resuscitation for Liver Disease
This trial is assessing the safety of using a dextrose solution to improve blood flow in high-risk liver transplant patients. The goal is to see if this method is as effective and safe as it has been in other surgical patients.
Hepatocellular Carcinoma Clinical Trials
View 10 Hepatocellular Carcinoma medical studies.
Atezolizumab + Bevacizumab for Hepatocellular Carcinoma
This trial will test whether a combination of two drugs can help treat liver cancer in patients who are eligible for transplantation. The drugs will be given for six months before the transplant procedure.
Vitamin D3 for Vitamin D Deficiency
The purpose of this study is to investigate the effect of two different doses of vitamin D3 (2000 IU vs. 4000 IU) on serum 25-hydroxyvitamin D (25OHD) levels in patients with hepatocellular carcinoma on the liver transplant list. The study will help determine the dose of vitamin D3 that is required for patients with liver cancer to reach a normal level of 25OHD in the blood.
Liver Transplant Clinical Trials With No Placebo
View 62 liver transplant medical studies that do not have a placebo group.
TIPS for Liver Cirrhosis
This trial will test whether TIPS creation leads to improved muscle mass, body composition and muscle function within the first 12 months after the procedure compared to a control group without TIPS, and whether these changes improve liver disease outcomes in patients awaiting liver transplantation.
Tacrolimus and Envarsus for Liver Transplant Complications
This trial will compare the neurologic side effects of two immunosuppressant drugs used in liver transplant patients. One drug is given twice daily, and the other is given once daily. The trial hypothesis is that the once-daily drug will cause fewer neurologic side effects.
View More Liver Transplant Trials
See another 35 many medical studies focused on liver transplant.
Frequently Asked Questions
Introduction to liver transplant
What are the top hospitals conducting liver transplant research?
When it comes to cutting-edge clinical trials in liver transplantation, several prestigious hospitals are leading the way. In Toronto, the University Health Network is at the forefront with five ongoing liver transplant trials. This renowned institution is dedicated to advancing the field of liver transplantation and improving patient outcomes through rigorous research. In Chicago, Northwestern University is making significant strides as well, currently conducting four active trials focused on liver transplants. With a commitment to innovation and excellence in healthcare, this hospital aims to revolutionize the field of liver transplantation. Similarly, the University of Pennsylvaniar transplant trials. This renowned institution is dedicated to advancing the field of liver transplantation and improving patient outcomes through rigorous research. In Chicago, Northwestern University is making significant strides as well, currently conducting four active trials focused on liver transplants. With a commitment to innovation and excellence in healthcare, this hospital aims to revolutionize the field of liver transplantation. Similarly, the University of Pennsylvania in Philadelphia has also invested in four active clinical trials for liver transplants, demonstrating their dedication to finding new solutions for patients awaiting life-saving procedures.
Furthermore,Toronto General Hospital shares its commitment by participating in three ongoing clinical trials for liver transplantations while continuing its legacy of providing state-of-the-art medical care.These collective efforts ensure that patients facing critical challenges have access to pioneering treatments and potential breakthroughs.
On the other side of North America,in San Francisco,the University of California presents itself as an invaluable contributor where researchers actively engage incarrying outthree distinctlivertransplanttrials;their devotion towards exploring innovative approaches manifests their unwavering dedication towards transforming lives through these groundbreaking studies.
These top-tier institutions serve not only as pillars within their respective communities but also exemplify how collaboration between medical professionals can lead to transformative advancements in organ transplantation.The expansive groundwork laid by such hospitals paves a path toward improved techniques,survival rates,and overall qualityof lifefor individuals suffering from end-stage liver disease.Every step taken towards enhancing our understanding and refining treatment options provides hope for individuals awaiting life-altering transplants—ultimately changing countless lives forever
Which are the best cities for liver transplant clinical trials?
When it comes to liver transplant clinical trials, several cities emerge as top contenders in advancing research and treatment options. New York, with 11 active trials, focuses on studies such as HIVD+/R+, Telemetric Intervention, and the VitaSmart Liver Machine Perfusion System. Chicago follows closely behind with 10 ongoing trials exploring interventions like "Liver FrailTy" intervention (LIFT) among others. Toronto also plays a significant role with its 9 active trials investigating live donor liver transplantation, PET MRI, and Deceased donor Liver Transplantation. These cities showcase remarkable dedication to pushing the boundaries of liver transplant research and offering hope for patients in need of this life-saving procedure.
Which are the top treatments for liver transplant being explored in clinical trials?
Clinical trials for liver transplant treatments are yielding promising results, with several notable contenders taking the spotlight. One of the leading options is Apabetalone, which has shown potential in improving outcomes after liver transplantation. Another noteworthy treatment being explored is FT-4202, which aims to address complications related to sickle cellr transplant treatments are yielding promising results, with several notable contenders taking the spotlight. One of the leading options is Apabetalone, which has shown potential in improving outcomes after liver transplantation. Another noteworthy treatment being explored is FT-4202, which aims to address complications related to sickle cell disease post-transplantation. Additionally, the drug Maralixibat is under investigation for its potential benefits in preventing bile acid-related complications following a liver transplant. With ongoing research and advancements, these treatments offer hope for enhancing patient outcomes in liver transplantation procedures.
What are the most recent clinical trials for liver transplant?
Exciting progress is being made in the field of liver transplant, with recent clinical trials exploring new possibilities and potential treatments. One such trial investigates the use of semaglutide pen injector, currently in Phase 2. This innovative approach aims to improve outcomes for liver transplant patients. Another study focuses on combining atezolizumab and bevacizumab in a Phase 4 trial, seeking to optimize immunosuppressive strategies for successful liver transplantation. Additionally, fenofibrate has shown promise as a treatment option through its ongoing Phase 2 trial. As researchers continue their efforts to enhance patient care, these advancements offer hope for individuals undergoing or awaiting a liver transplant procedure.
What liver transplant clinical trials were recently completed?
Recently completed clinical trials in the field of liver transplantation have yielded important findings, bringing hope to patients awaiting this life-saving procedure.